Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis
Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Rel...
Published in: | Journal of Tropical Medicine |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2022
|
Subjects: | |
Online Access: | https://doi.org/10.1155/2022/5071816 https://doaj.org/article/4e37c08fad02471dacf8b7066a62dfe3 |
id |
ftdoajarticles:oai:doaj.org/article:4e37c08fad02471dacf8b7066a62dfe3 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:4e37c08fad02471dacf8b7066a62dfe3 2024-09-09T19:26:48+00:00 Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou 2022-01-01T00:00:00Z https://doi.org/10.1155/2022/5071816 https://doaj.org/article/4e37c08fad02471dacf8b7066a62dfe3 EN eng Wiley http://dx.doi.org/10.1155/2022/5071816 https://doaj.org/toc/1687-9694 1687-9694 doi:10.1155/2022/5071816 https://doaj.org/article/4e37c08fad02471dacf8b7066a62dfe3 Journal of Tropical Medicine, Vol 2022 (2022) Arctic medicine. Tropical medicine RC955-962 article 2022 ftdoajarticles https://doi.org/10.1155/2022/5071816 2024-08-05T17:48:40Z Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Relevant randomized controlled trials (RCTs) were retrieved by searching the PubMed, Embase, Cochrane’s Library, Web of Science, Wanfang, and CNKI databases. A random-effects model was used to combine the results. Results. 18 RCTs with 2630 patients were included in this meta-analysis. Pooled results showed that adjunctive rhuIL-2 significantly increased the odds of sputum culture conversion to negative (risk ratio [RR]: 1.27, 95% CI: 1.09 to 1.47, p=0.002, I2 = 80%), sputum smear conversion to negative (RR: 1.35, 95% CI: 1.17 to 1.57, p<0.001, I2 = 83%), radiographic focus absorption (RR: 1.17, 95% CI: 1.06 to 1.30, p=0.002, I2 = 72), and cavity closure (RR: 1.24, 95% CI: 1.09 to 1.40, p<0.001, I2 = 23). The use of rhuIL-2 was not related to any severe adverse events which led to discontinuation of the treatment. Results showed that rhuIL-2 was related to an increased risk of fever (RR: 2.46, 95% CI: 1.29 to 4.70, p=0.006, I2 = 0%). The incidence of other adverse events, such as musculoskeletal pain, hepatic injury, and renal toxicity, was not significantly different between groups (p all >0.05). Conclusions. rhuIL-2 is an effective adjunctive immunotherapy for patients with pulmonary tuberculosis. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Journal of Tropical Medicine 2022 1 18 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 |
description |
Background. The results of previous clinical trials evaluating the efficacy and safety of recombinant human interleukin-2 (rhuIL-2) for adult patients with pulmonary tuberculosis showed inconsistent results. Accordingly, a comprehensive systematic review and meta-analysis was performed. Methods. Relevant randomized controlled trials (RCTs) were retrieved by searching the PubMed, Embase, Cochrane’s Library, Web of Science, Wanfang, and CNKI databases. A random-effects model was used to combine the results. Results. 18 RCTs with 2630 patients were included in this meta-analysis. Pooled results showed that adjunctive rhuIL-2 significantly increased the odds of sputum culture conversion to negative (risk ratio [RR]: 1.27, 95% CI: 1.09 to 1.47, p=0.002, I2 = 80%), sputum smear conversion to negative (RR: 1.35, 95% CI: 1.17 to 1.57, p<0.001, I2 = 83%), radiographic focus absorption (RR: 1.17, 95% CI: 1.06 to 1.30, p=0.002, I2 = 72), and cavity closure (RR: 1.24, 95% CI: 1.09 to 1.40, p<0.001, I2 = 23). The use of rhuIL-2 was not related to any severe adverse events which led to discontinuation of the treatment. Results showed that rhuIL-2 was related to an increased risk of fever (RR: 2.46, 95% CI: 1.29 to 4.70, p=0.006, I2 = 0%). The incidence of other adverse events, such as musculoskeletal pain, hepatic injury, and renal toxicity, was not significantly different between groups (p all >0.05). Conclusions. rhuIL-2 is an effective adjunctive immunotherapy for patients with pulmonary tuberculosis. |
format |
Article in Journal/Newspaper |
author |
Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou |
author_facet |
Lina Sheng Xiaofei Li Fangbin Weng Shuang Wu Yongxin Chen Lianqing Lou |
author_sort |
Lina Sheng |
title |
Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
title_short |
Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
title_full |
Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
title_fullStr |
Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
title_full_unstemmed |
Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis |
title_sort |
efficacy and safety of adjunctive recombinant human interleukin-2 for patients with pulmonary tuberculosis: a meta-analysis |
publisher |
Wiley |
publishDate |
2022 |
url |
https://doi.org/10.1155/2022/5071816 https://doaj.org/article/4e37c08fad02471dacf8b7066a62dfe3 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Journal of Tropical Medicine, Vol 2022 (2022) |
op_relation |
http://dx.doi.org/10.1155/2022/5071816 https://doaj.org/toc/1687-9694 1687-9694 doi:10.1155/2022/5071816 https://doaj.org/article/4e37c08fad02471dacf8b7066a62dfe3 |
op_doi |
https://doi.org/10.1155/2022/5071816 |
container_title |
Journal of Tropical Medicine |
container_volume |
2022 |
container_start_page |
1 |
op_container_end_page |
18 |
_version_ |
1809896358646120448 |